Glyriva Bexicap

• Chronic obstructive pulmonary disease (COPD): Maintenance bronchodilator treatment to relieve symptoms in adult patients

Glycopyrronium is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3-receptors at the smooth muscle results in relaxation. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD.

Adult Dose:

• One 50 microgram capsule once daily using the inhalation device
• Administered at the same time of the day
• Should not be taken more than one time every 24 hours

* Use as directed by the registered physician

Common Side Effects:

• Dry mouth
• Cough
• Nasopharyngitis
• Vomiting
• Musculoskeletal pain
• Insomnia
• Diabetes mellitus
• Gastroenteritis

Rare Side Effects: Paradoxical bronchospasm, angioedema, hypersensitivity, pruritus, sinus congestion.

Use in Pregnancy: Limited data in pregnant women. Use only if expected benefit justifies potential risk to the fetus.

Precautions:

• Not indicated for initial treatment of acute bronchospasm (rescue therapy)
• Should not be used in patients under 18 years
• Use with caution in narrow-angle glaucoma or urinary retention
• Discontinue if signs of allergic reaction occur
• Discontinue if paradoxical bronchospasm occurs

Overdose: High doses may lead to anticholinergic symptoms. Symptomatic treatment indicated. 100 and 200 microgram doses well tolerated for 28 days.

Storage: Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture.